

Title (en)
Sulfonylaminocarboxylic acids

Title (de)
Sulfonylaminocarbonsäuren

Title (fr)
Acides sulfonylaminocarboxyliques

Publication
EP 0877018 A1 19981111 (DE)

Application
EP 98108038 A 19980502

Priority
DE 19719621 A 19970509

Abstract (en)

Sulphonamide derivatives of formula (I) and their stereoisomers and salts are new. R₁ = Ar or Het; Ar = phenyl (optionally substituted by 1 or 2 alkyl, 3-6C cycloalkyl, OH, alkyl-COO-, alkyl-O-, alkyl-O-(1-4C alkylene)-O-, halo, CF₃, CN, NO₂, COOH, alkyl-O-CO-, OCH₂O, NR₄R₅CO and NR₄R₅); Het = pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, indolyl, benzothiophenyl, benzimidazolyl, benzoxazolyl or benzothiazolyl (all optionally substituted as for phenyl in Ar); R₂, R₄, R₅ = H, alkyl, carboxyalkyl, Ar-(CH₂)_n- (in which Ar is further optionally substituted by 2-4C alkanoylamino) or picolyl; or NR₄R₅ = 4-7 membered ring (optionally with one C replaced by O, S or NH and optionally having two adjacent C forming part of a benzene residue); n = 0-2; R₃ = H, 1-10C alkyl (optionally substituted by OH), 2-10C alkenyl, alkyl substituted by R₂O-, R₂S(O)n-, R₂S(O)n=NH- or a group of formula (ii); Ar-(CH₂)_m- (optionally substituted by OH in the (CH₂)_m chain and in which Ar is further optionally substituted by -O-(CH₂)_m-Ar and -CO(CH₂)_mAr); Het-(CH₂)_m- (optionally substituted by OH in the (CH₂)_m chain and in which Het is further optionally substituted by CHO, SO₂Ar and -O(CH₂)_m-Ph); -(CH₂)_m-P(O)(OH)-(1-3C alkyl) or R₆CO-alkyl-; or R₂+R₃ = (CH₂)_r (in which the obtained ring optionally has one ring C replaced by O, S or NR₇ and is optionally substituted by alkyl, Ph, (CH₂)_mPh and/or OH); W = O, S or N; m = 0-6; r = 1-4; R₆ = H, alkyl, Ar, Het or Het-(CH₂)_m-NH- (both further optionally ring-substituted by carboxy-(1-4C) alkyl), OH, OR₂, NR₄R₅, NHR₄R₅ or NHCHR₃COOH; R₇ = H, alkyl, Ar, CH₂Ar or R₂N-C(=NH)-; A = bond, O, CH=CH or C IDENTICAL C; B = (CH₂)_m, O(CH₂)_p or CH=CH; p = 1-5; X = CH=CH, O or S; and unless specified otherwise alkyl moieties have 1-6C. Also claimed are intermediates of formula (VI) (see "Preparation").

Abstract (de)

Verbindungen der Formel I <IMAGE> eignen sich zur Herstellung von Arzneimitteln zur Prophylaxe und Therapie von Erkrankungen, an deren Verlauf eine verstärkte Aktivität von Matrix-abbauenden Metalloproteinasen beteiligt ist.

IPC 1-7

C07C 311/19; **C07C 311/29**; **A61K 31/18**; **A61K 31/63**; **C07D 207/16**; **C07D 409/04**; **C07D 413/04**; **C07D 277/16**; **C07D 333/24**; **C07D 333/60**; **C07D 209/18**; **C07D 233/54**; **C07D 317/60**; **C07D 213/42**; **C07D 205/04**; **C07D 263/06**; **C07D 211/34**; **C07D 401/12**; **C07D 203/24**; **C07D 249/06**; **C07D 403/12**; **C07D 261/08**; **C07D 295/10**; **C07D 235/16**; **C07D 209/08**

IPC 8 full level

A61K 31/18 (2006.01); **A61K 31/195** (2006.01); **A61K 31/245** (2006.01); **A61K 31/275** (2006.01); **A61K 31/34** (2006.01); **A61K 31/36** (2006.01); **A61K 31/38** (2006.01); **A61K 31/381** (2006.01); **A61K 31/395** (2006.01); **A61K 31/396** (2006.01); **A61K 31/397** (2006.01); **A61K 31/40** (2006.01); **A61K 31/403** (2006.01); **A61K 31/404** (2006.01); **A61K 31/405** (2006.01); **A61K 31/41** (2006.01); **A61K 31/415** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/42** (2006.01); **A61K 31/421** (2006.01); **A61K 31/425** (2006.01); **A61K 31/426** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4427** (2006.01); **A61K 31/4433** (2006.01); **C07D 307/54** (2006.01); **A61K 31/445** (2006.01); **A61K 31/454** (2006.01); **A61K 31/63** (2006.01); **A61K 31/66** (2006.01); **A61K 31/665** (2006.01); **A61K 31/67** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 19/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07C 311/16** (2006.01); **C07C 311/19** (2006.01); **C07C 311/29** (2006.01); **C07C 311/37** (2006.01); **C07C 311/42** (2006.01); **C07C 311/44** (2006.01); **C07C 317/48** (2006.01); **C07C 323/51** (2006.01); **C07C 323/58** (2006.01); **C07C 323/59** (2006.01); **C07C 381/10** (2006.01); **C07D 203/06** (2006.01); **C07D 203/24** (2006.01); **C07D 205/04** (2006.01); **C07D 207/12** (2006.01); **C07D 207/16** (2006.01); **C07D 207/48** (2006.01); **C07D 209/08** (2006.01); **C07D 209/10** (2006.01); **C07D 209/18** (2006.01); **C07D 209/20** (2006.01); **C07D 211/96** (2006.01); **C07D 213/42** (2006.01); **C07D 213/55** (2006.01); **C07D 213/75** (2006.01); **C07D 233/20** (2006.01); **C07D 233/54** (2006.01); **C07D 233/64** (2006.01); **C07D 235/16** (2006.01); **C07D 249/06** (2006.01); **C07D 263/04** (2006.01); **C07D 277/16** (2006.01); **C07D 277/20** (2006.01); **C07D 277/36** (2006.01); **C07D 295/08** (2006.01); **C07D 307/58** (2006.01); **C07D 317/60** (2006.01); **C07D 333/22** (2006.01); **C07D 333/24** (2006.01); **C07D 333/34** (2006.01); **C07D 333/60** (2006.01); **C07D 401/12** (2006.01); **C07D 403/12** (2006.01); **C07D 409/04** (2006.01); **C07D 413/04** (2006.01); **C07F 9/30** (2006.01)

CPC (source: EP US)

A61P 9/00 (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 19/04** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/04** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07C 311/19** (2013.01 - EP US); **C07C 311/29** (2013.01 - EP US); **C07C 311/44** (2013.01 - EP US); **C07C 317/48** (2013.01 - EP US); **C07C 323/59** (2013.01 - EP US); **C07C 381/10** (2013.01 - EP US); **C07D 203/24** (2013.01 - EP US); **C07D 207/16** (2013.01 - EP US); **C07D 209/08** (2013.01 - EP US); **C07D 209/20** (2013.01 - EP US); **C07D 211/96** (2013.01 - EP US); **C07D 213/42** (2013.01 - EP US); **C07D 213/75** (2013.01 - EP US); **C07D 233/64** (2013.01 - EP US); **C07D 235/16** (2013.01 - EP US); **C07D 249/06** (2013.01 - EP US); **C07D 317/60** (2013.01 - EP US); **C07D 333/24** (2013.01 - EP US); **C07D 409/04** (2013.01 - EP US); **C07D 413/04** (2013.01 - EP US); **C07F 9/30** (2013.01 - EP US)

Citation (search report)

- [AD] EP 0757037 A2 19970205 - ONO PHARMACEUTICAL CO [JP]
- [AD] WO 9535276 A1 19951228 - BRITISH BIOTECH PHARM [GB], et al
- [AD] WO 9627583 A1 19960912 - PFIZER [US], et al
- [AD] EP 0606046 A1 19940713 - CIBA GEIGY AG [CH]
- [A] WO 9633172 A1 19961024 - PFIZER [US], et al
- [A] WO 9600214 A1 19960104 - CIBA GEIGY AG [CH], et al
- [AP] WO 9719068 A1 19970529 - WARNER LAMBERT CO [US], et al

Cited by

EP1493740A1; US6420396B1; EP1918278A1; US6335333B1; CZ302291B6; EP1208092A4; US10005733B2; WO2005003114A1; WO2005118528A3; WO0058278A1; US7576222B2; US7964643B2; US7659293B2; US6927219B2; US7291634B2; WO0027808A1; WO9942443A1; WO0170691A1; WO0004030A1; US7138432B1; US8034810B2; US8524778B2; US8435968B2; US8822507B2; US9050329B1;

US9302984B2; US9616037B2; US7176202B2; US7407956B2; US6852751B2; US6949545B2; US6235727B1; US6500811B2; US8207167B2; US6201130B1; US6410580B1; US9624167B2; US9796670B2; US10029979B2; US10233147B2; US7598242B2; US6838466B2; US7034057B2; US6677360B2; US7094911B2; US7214677B2; US7235549B2; US6566381B1; US6762198B2

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

EP 0877018 A1 19981111; EP 0877018 B1 20030502; AR 012674 A1 20001108; AT E238984 T1 20030515; AU 6482398 A 19981112; AU 732723 B2 20010426; BR 9801606 A 19990518; BR 9801606 B1 20100727; CA 2237099 A1 19981109; CA 2237099 C 20100810; CN 1205328 A 19990120; CN 1280267 C 20061018; CZ 143898 A3 19981111; CZ 295527 B6 20050817; DE 19719621 A1 19981112; DE 59808121 D1 20030605; DK 0877018 T3 20030825; ES 2195220 T3 20031201; HU 224959 B1 20060428; HU 9801044 D0 19980728; HU P9801044 A2 19990628; HU P9801044 A3 20000928; ID 20807 A 19990311; JP 4177483 B2 20081105; JP H1160551 A 19990302; KR 100572494 B1 20070425; KR 19980086847 A 19981205; PL 191876 B1 20060731; PL 326216 A1 19981123; PT 877018 E 20030930; RU 2193027 C2 20021120; TR 199800815 A2 19981123; TR 199800815 A3 19981123; US 2003087945 A1 20030508; US 6451824 B1 20020917; US 7160903 B2 20070109

DOCDB simple family (application)

EP 98108038 A 19980502; AR P980102139 A 19980507; AT 98108038 T 19980502; AU 6482398 A 19980508; BR 9801606 A 19980508; CA 2237099 A 19980507; CN 98115265 A 19980508; CZ 143898 A 19980507; DE 19719621 A 19970509; DE 59808121 T 19980502; DK 98108038 T 19980502; ES 98108038 T 19980502; HU P9801044 A 19980508; ID 980667 A 19980507; JP 16270698 A 19980508; KR 19980016385 A 19980508; PL 32621698 A 19980508; PT 98108038 T 19980502; RU 98108979 A 19980508; TR 9800815 A 19980507; US 17087002 A 20020613; US 7469398 A 19980508